Downloads: 86
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
j.bbmt.2018.10.014.pdf | 429.17 kB | Adobe PDF | View/Open |
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Watanabe, Mizuki | en |
dc.contributor.author | Kanda, Junya | en |
dc.contributor.author | Hishizawa, Masakatsu | en |
dc.contributor.author | Kondo, Tadakazu | en |
dc.contributor.author | Yamashita, Kouhei | en |
dc.contributor.author | Takaori-Kondo, Akifumi | en |
dc.contributor.alternative | 諫⽥, 淳也 | ja |
dc.contributor.alternative | 菱澤, 方勝 | ja |
dc.contributor.alternative | 近藤, 忠一 | ja |
dc.contributor.alternative | 山下, 浩平 | ja |
dc.contributor.alternative | 髙折, 晃史 | ja |
dc.date.accessioned | 2019-05-24T05:31:35Z | - |
dc.date.available | 2019-05-24T05:31:35Z | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 1083-8791 | - |
dc.identifier.issn | 1523-6536 | - |
dc.identifier.uri | http://hdl.handle.net/2433/241617 | - |
dc.description.abstract | Viral infection is a serious complication that can greatly affect patient mortality and morbidity after allogenic hematopoietic stem cell transplantation (allo-HSCT). For the early identification of patients at high risk for viral infection, we evaluated the impact of lymphocyte area under the curve (AUC) value as a new predictive factor for early immune reconstitution after allo-HSCT against viral infection. This study included 286 patients who underwent their first allo-HSCT at Kyoto University Hospital between 2005 and 2017. Lymphocyte AUC from day 0 to day +15 was calculated in the analysis of human herpesvirus 6 (HHV-6), and lymphocyte AUC from day 0 to day +30 was calculated in the analysis of other viruses (cytomegalovirus [CMV], adenovirus, BK virus, JC virus, and varicella zoster virus). The risk factors for each viral reactivation/infection were assessed by multivariate analysis. The median age at transplantation was 51 years (range, 17 to 68 years). The median lymphocyte AUC was 63/μL (range, 0 to 5620/μL) at day +15 and 3880 (range, 0 to 118, 260/μL) at day +30. An increase in lymphocyte AUC was significantly associated with a high frequency of HHV-6 reactivation (P = .033) and a low frequency of CMV antigenemia (P = .014). No apparent association was found between lymphocyte AUC and reactivation/infection of other viruses. Aplastic anemia as a primary disease (hazard ratio [HR], 5.34; P < .001) and cord blood as a donor source (HR, 3.05; P = .006) were other risk factors for HHV-6 reactivation. Other risk factors for CMV antigenemia included the occurrence of acute graft-versus-host disease (HR 2.21; P < .001) and recipient age (HR 1.55; P = .017). Higher lymphocyte AUC at day +30 was significantly associated with low treatment-related mortality (HR, .47; P = .045). Lymphocyte AUC may be a good predictive factor for immune reconstitution against CMV reactivation. It also provides valuable information for predicting HHV-6 reactivation and treatment-related mortality. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier Inc. | en |
dc.rights | © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | en |
dc.rights | The full-text file will be made open to the public on 1 March 2020 in accordance with publisher's 'Terms and Conditions for Self-Archiving'. | en |
dc.rights | この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 | ja |
dc.rights | This is not the published version. Please cite only the published version. | en |
dc.subject | Lymphocyte AUC | en |
dc.subject | HHV-6 | en |
dc.subject | CMV antigenemia | en |
dc.subject | Viral reactivation | en |
dc.subject | Immune reconstitution | en |
dc.title | Lymphocyte Area Under the Curve as a Predictive Factor for Viral Infection after Allogenic Hematopoietic Stem Cell Transplantation | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | Biology of Blood and Marrow Transplantation | en |
dc.identifier.volume | 25 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 587 | - |
dc.identifier.epage | 593 | - |
dc.relation.doi | 10.1016/j.bbmt.2018.10.014 | - |
dc.textversion | author | - |
dc.address | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | en |
dc.address | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | en |
dc.address | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | en |
dc.address | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | en |
dc.address | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | en |
dc.address | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | en |
dc.identifier.pmid | 30359733 | - |
dcterms.accessRights | open access | - |
datacite.date.available | 2020-03-01 | - |
Appears in Collections: | Journal Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.